Diplomat Pharmacy Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
FLINT, Mich., Oct. 16, 2014 /PRNewswire/ — Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation’s largest independent specialty pharmacy, today announced the closing of its initial public offering of 15,333,333 shares of common stock at an initial public offering price of $13.00 per share, which included 2,000,000 shares sold pursuant to the full exercise of the underwriters’ over-allotment option. Diplomat sold 11,000,000 shares of common stock and certain selling shareholders of Diplomat sold 4,333,333 shares of common stock. The company’s common stock is listed on the New York Stock Exchange under the symbol “DPLO.”
Credit Suisse Securities (USA) LLC and Morgan Stanley & Co. LLC acted as lead book-running managers. Additional book-running managers were J.P. Morgan Securities LLC and Wells Fargo Securities, LLC. William Blair & Company, L.L.C. and Leerink Partners LLC acted as co-managers.
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Copies of the prospectus related to the offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by telephone at (800) 221-1037, by facsimile at (212) 325-8057, or by email at email@example.com; or from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.
To learn more, visit diplomat.is.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues – always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Bob East, Westwicke Partners
443-213-0500 | Diplomat@westwicke.com
Jenny Cretu, Diplomat
810.768.9370 | firstname.lastname@example.org
@DiplomatRxWe are #hiring sales consultants for both NYC and Oakland, California! Come check it out. https://t.co/GDqMaItrsZ5 days ago
@gchabitatRT @gchabitat: Do you have what it takes to be a Habitat Olympian? Join us at @DiplomatRx on 5/5 to find out! https://t.co/5eq5y94hv36 days ago
@DiplomatRxDiplomat Will Dispense ZEJULA™ to Treat Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer… https://t.co/MnQRQdLufl1 week ago
@DiplomatRxFar more than an adventure, their trip was dedicated to assisting people living with #hemophilia… https://t.co/kngmnkvjvU2 weeks ago
@DiplomatRxDiplomat to Release First Quarter 2017 Operating Results and Host Conference Call on Monday, May 8, 2017… https://t.co/h6vJR7823O2 weeks ago